P-gp transporter is one of the major barriers that limit the oral absorption of active chemotherapy drugs in humans. However, certain drugs with P-gp liabilities may also have liabilities for other barriers such as metabolizing enzymes, primarily the cytochrome P450 isoenzymes (CYPs). These CYPs limit oral absorption of certain drugs by metabolizing drugs within the gastrointestinal tract before they can be absorbed.

We are developing a proprietary class of “dual” absorption enhancers to inhibit both the P-gp transporter and the CYP enzymes within the gastrointestinal tract. This class of dual absorption enhancers has shown potential to significantly improve the oral bioavailability of certain other drugs in laboratory tests. With this technology platform, we may be able to expand the application of our oral absorption platform to drugs with P-gp and CYP liabilities and develop better performing next- generation oral medicines in our pipeline. The development of these dual absorption enhancers is at the preclinical stage.